Melissa L. Johnson - Publications, H-index & Citations

Melissa L. Johnson

university of london

65H指数

835论文数

2.3W被引数

收录论文 136

发表时间

SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation SKYSCRAPER-03研究：比较替拉戈鲁单抗联合阿替利珠单抗与度伐利尤单抗治疗局部晚期、不可切除的III期非小细胞肺癌（接受铂类为基础的同步化放疗后）的III期研究

Annals of Oncology

IF65.4

2026-08-06

PREAI

H.A. Wakelee; M-J. Ahn; J. Bradley; S. Popat; K. Kelly; A-M. Baird; O. Ozyilkan; J. Yu; S.Y. Lee; N. Yanagitani; M. Johnson; A. Sánchez-Hernández; A. Szczesna; K. Cuppens; E. Yao; C. Parsons; C. Matheny; Z. Zhang; M.N. White; J.J. Hsu

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer AZD2811在复发/难治性小细胞肺癌的I期剂量扩展研究中通过生物标志物分析进行疗效监测

British Journal of Cancer

IF6.8

2026-04-03

OAAI

Melissa L. Johnson; Giulia Fabbri; Carmela Ciardullo; Judy S. Wang; Gerald S. Falchook; Suzanne Jones; Donald Strickland; Jacob Sands; Carl M. Gay; Robert J. Cardnell; Luis Tobalina; Sophie E. Willis; Jaime Rodriguez-Canales; Myria Nikolaou; Emma V. Jones; Stein Schalkwijk; Liz Sainsbury; Alexander MacDonald; Philip Overend; Caroline Kennedy; J. Elizabeth Pease; Philip Szekeres; Jan Cosaert; Howard Burris; Lauren A. Byers

Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial Ifinatamab deruxtecan，一种B7-H3靶向抗体—药物偶联物，在晚期实体瘤患者中的研究（IDeate-PanTumor01）：一项1/2期试验的剂量递增结果

The Lancet Oncology

IF0

2026-03-30

PREAI

Melissa L Johnson; Manish R Patel; Gerald S Falchook; Takafumi Koyama; Martin Gutierrez; Mark M Awad; Sarina A Piha-Paul; Claire F Friedman; Taroh Satoh; Naoko Okamoto; Jasmeet Singh; Naoto Yoshizuka; Hillarie Plessner Windish; Meng Qian; Brittany P Tran; Toshihiko Doi

Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1 度瓦尼单抗联合齐木利单抗作为PD-L1高表达、晚期非小细胞肺癌患者的一线治疗：来自随机II期ARC-10研究的结果，第一部分

Lung Cancer

IF4.4

2026-02-11

OAAI

Jarushka Naidoo; Solange Peters; Yotsawaj Runglodvatana; Jacky Yu-Chung Li; Chin Heng Fong; Gwo Fuang Ho; Soon Hin How; Jitlada Juengsamarn; Julie R Graham; Neyssa Marina; Thao Dang; Deepa Patel; Sasha Han; Candy Bermingham; Melissa L Johnson

TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer

Clinical Lung Cancer

IF3.3

2026-01-26

PREAI

Luis G. Paz-Ares; Kenneth John O'Byrne; Melissa L. Johnson; Martin Reck; Nicolas Girard; Hidetoshi Hayashi; Caicun Zhou; Vishwanath Suresh Gharpure; Radhika Pisupati; Misena Pacius; Neal E. Ready

MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors MDX-2001-101研究方案：一项评估MDX2001单药治疗在晚期实体瘤患者中的I/IIa期、多中心、首次人体、开放标签临床试验

Future Oncology

IF2.6

2026-01-01

OAAI

Dumbrava, Ecaterina; Minchom, Anna; Henry, Jason; Johnson, Melissa; Sommerhalder, David; Merchan, Jaime; Heist, Rebecca; Cabanas, Elena Garralda; Cotreau, Monette; Goenaga, Anne-Laure; Burzyn, Dalia; Makris, Lukas; Culm, Kerry; Abbadessa, Giovanni

Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer 阿达沃塞替布（Adavosertib，一种Wee1抑制剂）联合多西他赛或卡铂联合培美曲塞治疗非小细胞肺癌的II期临床试验两例。

Targeted Oncology

IF4

2025-11-10

OAAI

Melissa L. Johnson; Shaker R. Dakhil; J. Thaddeus Beck; Ahad Sadiq; Smitha Menon; Ganesh M. Mugundu; Juliann Chmielecki; David R. Spigel

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast II期COPERNICUS研究：皮下注射Amivantamab联合Lazertinib作为一线治疗，或与化疗联合作为二线治疗，用于EGFR突变非小细胞肺癌的播客视频

Oncology and Therapy

IF3.2

2025-10-11

OAAI

Balazs Halmos; Narjust Florez; Sarah Goldberg; Wade Iams; Xiuning Le; Ticiana Leal; Danny Nguyen; Luis E. Raez; Jonathan W. Riess; Joshua Sabari; David Bjork; Nichelle Stigger; Yichuan Xia; Paul Cifuentes; Denise D’Andrea; Farah Shanoon; Andy L. Johnson; Melissa L. Johnson

A Response to the Letter to the Editor: “POSEIDON’s Missing Piece: Unanswered Questions on PFS Data in High-Risk Subgroups”对编辑信件的回应：“POSEIDON的缺失环节：高风险亚组中PFS数据的相关未解决问题”

Journal of Thoracic Oncology

IF20.8

2025-06-06

PREAI

Solange Peters; Byoung Chul Cho; Melissa L. Johnson

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report 更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

Journal of Thoracic Oncology

IF20.8

2025-06-04

OAAI

Gregory J. Riely; Myung-Ju Ahn; Jeffrey M. Clarke; Ibiayi Dagogo-Jack; Raymond Esper; Enriqueta Felip; Francesco Gelsomino; Jonathan W. Goldman; Maen Hussein; Melissa Johnson; Kristen A. Marrone; Daniel Morgensztern; Ernest Nadal; Marcelo V. Negrao; Michael Offin; Mariano Provencio; Suresh S. Ramalingam; Logan Roof; Rachel E. Sanborn; Egbert F. Smit; Anne Tsao; Tiziana Usari; Ann Alcasid; Keith Wilner; Svitlana Tonkovyd; Xiaosong Zhang; Bruce E. Johnson

A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors 一项关于抗CEACAM6抗体Tinurilimab（BAY 1834942）在晚期实体瘤患者中的I期研究

Targeted Oncology

IF4

2025-06-04

PREAI

Lillian L. Siu; David S. Hong; Wolf-Dietrich Döcke; Reimo Tetzner; Mark Trautwein; Charles Phelps; Joerg Willuda; Xiang Qing Yu; Hendrik Nogai; Melissa Johnson; Boon Cher Goh

A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect level 一种利用群体剂量-反应模型确定最小预期生物效应水平，以进行首次人体试验剂量选择的新方法

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2025-04-27

PREAI

Lin Yuan; Meghana Kulkarni; Evan Chiswick; Cheryl Koh; Peter Sandy; Salah Nabhan; Woody Sherman; Melissa Johnson; Judy Wang; Gerald Falchook; Jennifer Johnson; Christopher Winter; Humphrey Gardner; Arijit Chakravarty; Madison Stoddard

Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies I期IMCnyeso研究，该研究是一种靶向NY-ESO-1表达性恶性病变的T细胞受体双特异性ImmTAC。

CELL REPORTS MEDICINE

IF10.6

2025-04-01

OAAI

Lopez, Juanita S.; Milhem, Mohammed; Butler, Marcus O.; Thistlethwaite, Fiona; Van Tine, Brian A.; D'Angelo, Sandra P.; Johnson, Melissa L.; Sato, Takami; Arkenau, Hendrik-Tobias; Edukulla, Ramakrishna; Wustner, Jason; Marshall, Shannon; Rodon, Jordi

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary

FUTURE ONCOLOGY

IF2.6

2025-03-01

OAAI

de Langen, Adrianus Johannes; Johnson, Melissa L.; Mazieres, Julien; Dingemans, Anne-Marie C.; Mountzios, Giannis; Pless, Miklos; Wolf, Juergen; Schuler, Martin; Lena, Herve; Skoulidis, Ferdinandos; Yoneshima, Yasuto; Kim, Sang-We; Linardou, Helena; Novello, Silvia; van der Wekken, Anthonie J.; Chen, Yuanbin; Peters, Solange; Felip, Enriqueta; Solomon, Benjamin J.; Ramalingam, Suresh S.; Dooms, Christophe; Lindsay, Colin R.; Ferreira, Carlos Gil; Blais, Normand; Obiozor, Cynthia C.; Wang, Yang; Mehta, Bhakti; Varrieur, Tracy; Ngarmchamnanrith, Gataree; Stollenwerk, Bjoern; Waterhouse, David; Paz-Ares, Luis

First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma

INVESTIGATIONAL NEW DRUGS

IF2.7

2025-03-01

PREAI

Johnson, Melissa; Hong, David; Brana, Irene; Schoffski, Patrick; Galvao, Vladimir; Rangwala, Fatima; Ma, Bo; Hernandez, Robert; Kamat, Asha; Kato, Kazunobu; Schreiber, Taylor H.; Pandite, Lini; Siu, Lillian L.

Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial 先前接受过Tarlatamab治疗的小细胞肺癌患者的患者报告结局: DeLLphi-301 2期试验的结果

ADVANCES IN THERAPY

IF4

2025-03-01

OAAI

Hummel, Horst-Dieter; Ahn, Myung-Ju; Blackhall, Fiona; Reck, Martin; Akamatsu, Hiroaki; Ramalingam, Suresh S.; Borghaei, Hossein; Johnson, Melissa; Dirnberger, Franziska; Cocks, Kim; Huang, Shuang; Mukherjee, Sujoy; Paz-Ares, Luis

Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)( vol 197 , 107960 , 2024)真实世界中索托拉西比相较于多西他赛在二线及二线以上治疗中晚期非小细胞肺癌（NSCLC）患者的比较疗效（vol 197, 107960, 2024）

LUNG CANCER

IF4.4

2025-02-01

OAAI

Johnson, Melissa; Younan, Diana; Kent, Shia T.; Frias, Marco Mesa; Brookhart, M. Alan; Balasubramanian, Akhila; Spira, Alexander

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

MOLECULAR CANCER THERAPEUTICS

IF5.5

2024-12-31

OAAI

Johnson, Melissa L.; Wolf, Beni B.; Wang, Judy S.; Philipovskiy, Alexander; Shapiro, Geoffrey I.; Bockorny, Bruno; Guo, Wei; Shen, Jinshan; Jen, Kai Yu; Lerose, Marybeth; Hunter, Tamieka Lauz; Padval, Mahesh; Schmidt-Kittler, Oleg; Bhatia, Namrata; Dubey, Sarita; Suchomel, Julia; Bendell, Johanna C.; Jauhari, Shekeab; Eng-Wong, Jennifer; Lin, Jessica J.

A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases 关于EGFR突变的NSCLC脑转移患者的抗体药物偶联物颅内疗效的播客讨论

ONCOLOGY AND THERAPY

IF3.2

2024-12-18

OAAI

Johnson, Melissa L.; Lin, Jessica J.; Boire, Adrienne; Khandekar, Melin J.; Yu, Helena A.

Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC

FRONTIERS IN ONCOLOGY

IF3.3

2024-12-05

OAAI

Shiller, Michelle; Johnson, Melissa; Auber, Robert; Patel, Sandip Pravin

研究方向